期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
逆转录酶抑制剂——Rilpivirine 被引量:1
1
作者 康银花 范鸣 《药学进展》 CAS 2008年第6期282-284,共3页
关键词 rilpivirine 逆转录酶抑制剂 HIV-1感染
下载PDF
Role of Ligand Reorganization and Conformational Restraints on the Binding Free Energies of DAPY Non-Nucleoside Inhibitors to HIV Reverse Transcriptase
2
作者 Emilio Gallicchio 《Computational Molecular Bioscience》 2012年第1期7-22,共16页
The results of computer simulations of the binding of etravirine (TMC125) and rilpivirine (TMC278) to HIV reverse transcriptase are reported. It is confirmed that consistent binding free energy estimates are obtained ... The results of computer simulations of the binding of etravirine (TMC125) and rilpivirine (TMC278) to HIV reverse transcriptase are reported. It is confirmed that consistent binding free energy estimates are obtained with or without the application of torsional restraints when the free energies of imposing the restraints are taken into account. The restraints have a smaller influence on the thermodynamics and apparent kinetics of binding of TMC125 compared to the more flexible TMC278 inhibitor. The concept of the reorganization free energy of binding is useful to understand and categorize these effects. Contrary to expectations, the use of conformational restraints did not consistently enhance convergence of binding free energy estimates due to suppression of binding/unbinding pathways and due to the influence of rotational degrees of freedom not directly controlled by the restraints. Physical insights concerning the thermodynamic driving forces for binding and the role of “jiggling” and “wiggling” motion of the ligands are discussed. Based on these insights we conclude that an ideal inhibitor, if chemically realizable, would possess the electrostatic charge distribution of TMC125, so as to form strong interactions with the receptor, and the larger and more flexible substituents of TMC278, so as to minimize reorganization free energy penalties and the effects of resistance mutations, suitably modified, as in TMC125, so as to disfavor the formation of non-binding competent extended conformations when free in solution. 展开更多
关键词 HIV-RT TMC125 TMC278 ETRAVIRINE rilpivirine BINDING Free Energy
下载PDF
二芳基嘧啶类HIV-1非核苷类逆转录酶抑制剂研究进展
3
作者 田兴涛 谢蓝 《药学学报》 CAS CSCD 北大核心 2010年第2期177-183,共7页
2008年FDA批准上市的新一代非核苷类逆转录酶抑制剂Etravirine(TMC125)和Ⅲ期临床候选药Rilpivirine(TMC278)都是二芳基嘧啶(DAPY)类化合物,均对HIV野生型和多种耐药性病毒株有相当强的抑制作用。DAPY类药物的发现和发展是多学科合作研... 2008年FDA批准上市的新一代非核苷类逆转录酶抑制剂Etravirine(TMC125)和Ⅲ期临床候选药Rilpivirine(TMC278)都是二芳基嘧啶(DAPY)类化合物,均对HIV野生型和多种耐药性病毒株有相当强的抑制作用。DAPY类药物的发现和发展是多学科合作研发新药的成功范例。本文综述了新一代HIV非核苷类逆转录酶抑制剂DAPY类化合物的发现、发展及最新研究进展。 展开更多
关键词 人类免疫缺陷病毒 非核苷类逆转录酶抑制剂 二芳基嘧啶类化合物 ETRAVIRINE rilpivirine
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部